MedTrace Logo

A Selective Androgen Receptor Modulator for Symptom Management in Prostate Cancer

NCT02499497 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 114

Last updated 2021-09-28

Study results available
· View outcomes & findings →

Summary

This research study is studying the use of a targeted therapy called LY SARM, which is an investigational drug from a new class of molecules called Selective Androgen Receptor Modulators (SARMs) as a possible improvement in quality of life for participants who have undergone radical prostatectomy. Androgens are a group of hormones that play a role in male traits and reproductive activity.

The names of the study interventions involved in this study are:

\- LY2452473

Conditions

Interventions

DRUG

LY2452473

LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.

DRUG

Placebo

The participants will receive pills containing no active drug.

Sponsors & Collaborators

Principal Investigators

  • Shalender Bhasin, MD · Brigham and Women's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2020-10-31
Completion
2020-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02499497 on ClinicalTrials.gov